Sep. 2 at 1:48 PM
$MDCX On the verge of a breakout after that game-changing news hit this morning. 🚀2.05$ breakout is key !!
🚨 Medicus Pharma (
$MDCX) has officially closed the acquisition of Antev Ltd., bringing in Teverelix — a next-gen GnRH antagonist with blockbuster potential.
Teverelix is positioned as a first-in-class treatment for acute urinary retention (AURr) and a best-in-class option for advanced prostate cancer patients with high cardiovascular risk. Together, these indications represent a
$6B+ market opportunity.
Adding to the excitement, veteran pharma executive Patrick J. Mahaffy (ex-Clovis, ex-Pharmion) has joined the board, strengthening leadership as
$MDCX advances multiple Phase 2b trials.
This deal supercharges Medicus’s pipeline and sets the stage for major near-term catalysts. 🚀📈
Website: https://medicuspharma.com
Communicated Disclaimer : https://tinyurl.com/2afx6epb
Peers:
$CRBP $SKYE $ADAG $COYA
